Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free SYRS Stock Alerts

Syros Pharmaceuticals (SYRS) Competitors

Syros Pharmaceuticals logo
$0.0004 0.00 (0.00%)
As of 09:30 AM Eastern
Compare

SYRS vs. SISI, CDT, BPTH, CARM, and SCPS

Should you buy Syros Pharmaceuticals stock or one of its competitors? Syros Pharmaceuticals's main competitors and comparable companies include Shineco (SISI), CDT Equity (CDT), Bio-Path (BPTH), Carisma Therapeutics (CARM), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Syros Pharmaceuticals compare to Shineco?

Shineco (NASDAQ:SISI) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Shineco has a beta of -1.76, indicating that its share price is 276% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Shineco has higher revenue and earnings than Syros Pharmaceuticals. Shineco is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shineco$9.60M0.00-$22.45M-$204.00N/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

Syros Pharmaceuticals has a net margin of 0.00% compared to Shineco's net margin of -380.55%. Shineco's return on equity of -79.89% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Shineco-380.55% -79.89% -33.01%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

4.1% of Shineco shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.80 beat Shineco's score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Shineco Neutral
Syros Pharmaceuticals Positive

Summary

Syros Pharmaceuticals beats Shineco on 8 of the 12 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to CDT Equity?

CDT Equity (NASDAQ:CDT) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

CDT Equity's return on equity of -72.25% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CDT EquityN/A -72.25% -55.44%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

In the previous week, CDT Equity had 3 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for Syros Pharmaceuticals. CDT Equity's average media sentiment score of 1.32 beat Syros Pharmaceuticals' score of 0.80 indicating that CDT Equity is being referred to more favorably in the media.

Company Overall Sentiment
CDT Equity Positive
Syros Pharmaceuticals Positive

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 7.3% of CDT Equity shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Syros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CDT Equity has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

CDT Equity has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CDT EquityN/AN/A-$39.22M-$83.86 thousandN/A
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

Summary

CDT Equity beats Syros Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Bio-Path?

Syros Pharmaceuticals (NASDAQ:SYRS) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bio-Path's return on equity of -2,842.40% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Bio-Path N/A -2,842.40%-337.48%

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.80 beat Bio-Path's score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Syros Pharmaceuticals Positive
Bio-Path Neutral

Bio-Path has lower revenue, but higher earnings than Syros Pharmaceuticals. Bio-Path is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Bio-PathN/AN/A-$16.08M-$1.09N/A

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.44, meaning that its stock price is 144% less volatile than the broader market.

Summary

Syros Pharmaceuticals beats Bio-Path on 7 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Carisma Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A

Carisma Therapeutics has a beta of -9.6, meaning that its share price is 1,060% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Syros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.80 beat Carisma Therapeutics' score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Carisma Therapeutics Neutral
Syros Pharmaceuticals Positive

Summary

Syros Pharmaceuticals beats Carisma Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Scopus BioPharma?

Syros Pharmaceuticals (NASDAQ:SYRS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Scopus BioPharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Scopus BioPharma N/A N/A N/A

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.80 beat Scopus BioPharma's score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Syros Pharmaceuticals Positive
Scopus BioPharma Neutral

Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market.

Scopus BioPharma has lower revenue, but higher earnings than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.03-$164.57M-$3.03N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Summary

Syros Pharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.

Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRS vs. The Competition

Export
MetricSyros PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.65M$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00626.67195.9718.94
Price / Sales0.03746.64564.5078.56
Price / CashN/A84.0876.6852.75
Price / Book0.009.1510.515.92
Net Income-$164.57M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-4.55%-4.32%-4.38%
1 Month PerformanceN/A-8.50%-8.64%-7.25%
1 Year PerformanceN/A-6.15%2.05%-4.95%

Syros Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-92.0%$1.65M$386KN/A120
SISI
Shineco
N/A$0.11
flat		N/A-88.3%$44K$9.60MN/A119
CDT
CDT Equity
0.5388 of 5 stars		$0.92
+0.5%		N/A-100.0%$28KN/AN/A4
BPTH
Bio-Path
N/A$0.00
flat		N/A-99.6%$27KN/AN/A10
CARM
Carisma Therapeutics
N/A$0.00
flat		N/A-98.9%$21K$10.77M0.0020

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SYRS) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
You’d Never Guess What Their European Chalet Cost
Eric and Debbie, a couple in their 60s from Burbank, California, retired to a private chalet on a European cou...
International Living | Sponsoredtc pixel